Novo Nordisk (NVO) and Eli Lilly (LLY) do not have a weight-loss drug partnership with telehealth website Mangoceuticals (MGRX), spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers, according to Reuters. Earlier, Mangoceuticals had announced the launch of MangoRx Direct and PeachesRx Direct, two integrated programs that according to the company provide direct access to authentic Zepbound from Eli Lilly and Wegovy from Novo Nordisk. Shares of Mangoceuticals are sliding more than 16% in afternoon trading.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly says ‘no affiliation’ with Mangoceuticals
- Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform
- Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition
- Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk
- Eli Lilly price target raised to $1,171 from $1,090 at Morgan Stanley